Strategic Partnerships Clonexpress offers patient-specific differentiated cell lines and custom tumor cell line development, presenting a strong opportunity for collaboration with pharma and contract research organizations seeking innovative models for drug discovery, toxicity testing, and personalized medicine programs.

Cancer Platform The discovery of a common growth control mechanism across cancers and a sensitive assay for targeting enables potential license or co-development deals with oncology companies aiming to create new cancer therapies with minimized side effects.

CNS and Neurobiology New human microglial and dopaminergic neuron cell lines along with CNS primary cells open doors for partnerships with neuroscience-focused firms and academic labs for preclinical studies, neurodegenerative disease research, and compound screening.

Licensing Opportunities Available cell lines for licensing or purchase across pancreatic beta, hepatocyte, and islet models provide tangible avenues for CROs and drug developers needing high-fidelity in vitro models for metabolism, insulin release, and toxicology assessments.

Funding and Scale With revenue in the low millions and a scalable platform built on epigenetic induction, there is potential to attract strategic investors or co-development funding for expansion, including larger-scale collaborations with mid-to-large biotech players.